CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma

Summary Despite the clinical and molecular heterogeneity of follicular lymphoma (FL), there remains a lack of biomarker‐directed therapeutic approaches in routine clinical practice, with the notable exception of the EZH2 inhibitor tazemetostat in EZH2‐mutant FL. Here we examined whether gene mutatio...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	British journal of haematology Ročník 205; číslo 5; s. 1804 - 1809
Hlavní autoři:	Kumar, Emil Arjun, Korfi, Koorosh, Bewicke‐Copley, Findlay, Close, Karina, Heward, James, Witzig, Thomas, Leukam, Michael, Ansell, Stephen, Scott, Jessica, Clear, Andrew, Efeyan, Alejo, Green, Michael, Siebert, Reiner, Peck, Barrie, Calaminici, Maria, Wang, Jun, Smith, Sonali, Novak, Anne, Fitzgibbon, Jude, Okosun, Jessica
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Blackwell Publishing Ltd 01.11.2024
Témata:	Aged Biomarkers Biopsy Clinical trials CREB-Binding Protein - genetics CREBBP Everolimus - therapeutic use Female follicular lymphoma genetics Histone acetyltransferase Humans Lymphoma Lymphoma, Follicular - drug therapy Lymphoma, Follicular - genetics Male Middle Aged mTOR inhibition MTOR Inhibitors - pharmacology MTOR Inhibitors - therapeutic use Mutation mutation analysis Point mutation Protein Domains Recurrence Sirolimus - analogs & derivatives TOR protein TOR Serine-Threonine Kinases - antagonists & inhibitors mTOR inhibition CREBBP genetics follicular lymphoma mutation analysis
ISSN:	0007-1048, 1365-2141, 1365-2141
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!